2024
An Open-Label Study of Subcutaneous CpG Oligodeoxynucleotide (PF03512676) in Combination with Trastuzumab in Patients with Metastatic HER2+ Breast Cancer
Quiroga D, Wesolowski R, Zelinskas S, Pinette A, Benner B, Schwarz E, Savardekar H, Johnson C, Stiff A, Yu L, Macrae E, Lustberg M, Mrozek E, Ramaswamy B, Carson W. An Open-Label Study of Subcutaneous CpG Oligodeoxynucleotide (PF03512676) in Combination with Trastuzumab in Patients with Metastatic HER2+ Breast Cancer. Cancer Control 2024, 31: 10732748241250189. PMID: 38797949, PMCID: PMC11129578, DOI: 10.1177/10732748241250189.Peer-Reviewed Original ResearchConceptsMetastatic HER2+ breast cancerHER2+ breast cancerStable diseaseBreast cancerCpG-ODNTrastuzumab treatmentTreated patientsHuman epidermal growth factor receptor 2 (HER2)-positiveToll-like receptor 9 agonistHER2-positive breast cancerWeek 2Immune profile changesPeripheral blood mononuclear cellsAdvanced/metastatic breast cancerVEGF-D levelsOpen-label phaseNK cell populationEfficacy of current treatmentsOpen-label studyAggressive breast cancerBlood mononuclear cellsCompared to baselineMedian PFSMetastatic HER2Monocytic MDSCs
2023
Quantitative cardiovascular magnetic resonance findings and clinical risk factors predict cardiovascular outcomes in breast cancer patients
Kwan J, Arbune A, Henry M, Hu R, Wei W, Nguyen V, Lee S, Lopez-Mattei J, Guha A, Huber S, Bader A, Meadows J, Sinusas A, Mojibian H, Peters D, Lustberg M, Hull S, Baldassarre L. Quantitative cardiovascular magnetic resonance findings and clinical risk factors predict cardiovascular outcomes in breast cancer patients. PLOS ONE 2023, 18: e0286364. PMID: 37252927, PMCID: PMC10228774, DOI: 10.1371/journal.pone.0286364.Peer-Reviewed Original ResearchConceptsBreast cancer patientsSystolic heart failureCardiovascular outcomesCancer patientsHeart failureValvular diseaseStrain abnormalitiesLeft ventricular ejection fraction reductionCancer treatment-related cardiotoxicityCardiovascular magnetic resonance findingsVentricular ejection fraction reductionYale-New Haven HospitalEjection fraction reductionTreatment-related cardiotoxicityAdverse cardiovascular outcomesClinical risk factorsNormal LV functionGlobal longitudinal strainIschemic heart diseaseMagnetic resonance findingsRisk regression modelsNew Haven HospitalSubclinical cardiotoxicityDiastolic dysfunctionStatin use
2018
Usefulness of Integrating Heart Failure Risk Factors Into Impairment of Global Longitudinal Strain to Predict Anthracycline-Related Cardiac Dysfunction
Milks M, Velez M, Mehta N, Ishola A, Van Houten T, Yildiz V, Reinbolt R, Lustberg M, Smith S, Orsinelli D. Usefulness of Integrating Heart Failure Risk Factors Into Impairment of Global Longitudinal Strain to Predict Anthracycline-Related Cardiac Dysfunction. The American Journal Of Cardiology 2018, 121: 867-873. PMID: 29454478, DOI: 10.1016/j.amjcard.2017.12.022.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnthracyclinesAntibiotics, AntineoplasticAntineoplastic Agents, ImmunologicalAtrial FibrillationAtrial FlutterBreast NeoplasmsCoronary Artery DiseaseDiabetes MellitusDoxorubicinEchocardiographyFemaleHeart FailureHumansHypertensionLogistic ModelsMiddle AgedRenal InsufficiencyReproducibility of ResultsRetrospective StudiesRisk AssessmentRisk FactorsStroke VolumeTrastuzumabVentricular DysfunctionConceptsCancer therapeutics-related cardiac dysfunctionGlobal longitudinal strainRisk factorsEchocardiographic variablesCardiac dysfunctionLongitudinal strainImaging assessmentCertain clinical risk factorsHeart failure risk factorsVentricular global longitudinal strainLeft ventricular longitudinal strainClinical risk factorsLV ejection fractionVentricular longitudinal strainHigh-risk groupRisk prediction toolsFailure risk factorsReceiver-operating characteristicClinical factorsEjection fractionOncologic treatmentLV functionRetrospective studyClinical variablesBreast cancer
2015
Neoadjuvant Dual HER2‐Targeted Therapy With Lapatinib and Trastuzumab Improves Pathologic Complete Response in Patients With Early Stage HER2‐Positive Breast Cancer: A Meta‐Analysis of Randomized Prospective Clinical Trials
Hicks M, Macrae E, Abdel‐Rasoul M, Layman R, Friedman S, Querry J, Lustberg M, Ramaswamy B, Mrozek E, Shapiro C, Wesolowski R. Neoadjuvant Dual HER2‐Targeted Therapy With Lapatinib and Trastuzumab Improves Pathologic Complete Response in Patients With Early Stage HER2‐Positive Breast Cancer: A Meta‐Analysis of Randomized Prospective Clinical Trials. The Oncologist 2015, 20: 337-343. PMID: 25732265, PMCID: PMC4391765, DOI: 10.1634/theoncologist.2014-0334.Peer-Reviewed Original ResearchConceptsAddition of lapatinibHER2-positive breast cancerNeoadjuvant chemotherapyBreast cancerLymph nodesClinical trialsEarly-stage HER2-positive breast cancerSan Antonio Breast Cancer SymposiumPathologic complete response rateEarly-stage breast cancerResidual invasive cancerResidual invasive carcinomaComplete response rateOperable breast cancerAxillary lymph nodesPathologic complete responseProspective clinical trialsStage breast cancerRates of pCRDual HER2NAC armProspective RCTsCancer SymposiumPCR rateComplete response
2014
A Phase II study of bevacizumab in combination with trastuzumab and docetaxel in HER2 positive metastatic breast cancer
Zhao M, Pan X, Layman R, Lustberg M, Mrozek E, Macrae E, Wesolowski R, Carothers S, Puhalla S, Shapiro C, Ramaswamy B. A Phase II study of bevacizumab in combination with trastuzumab and docetaxel in HER2 positive metastatic breast cancer. Investigational New Drugs 2014, 32: 1285-1294. PMID: 24894652, PMCID: PMC4303337, DOI: 10.1007/s10637-014-0122-5.Peer-Reviewed Original ResearchConceptsProgression-free survivalLeft ventricular ejection fractionClinical benefit rateHER2-positive MBCObjective response rateComplete responsePartial responseBreast cancerStable diseaseFree survivalGrade 3HER2-positive metastatic breast cancerResponse rateAdditional overall survival benefitsMedian progression-free survivalMetastatic breast cancer patientsPositive metastatic breast cancerVascular epithelial growth factorCommon grade 3Cycles of bevacizumabGrade 2 hypertensionMethods Eligible patientsPrior chemotherapy regimensCombination of bevacizumabHand-foot syndrome